GSK warns on profits as weak lung drug sales hit

A run of weak quarters highlights the pressure on Chief Executive Andrew Witty, whose drive to reshape Britain's biggest drugmaker has yet to deliver the hoped-for return to sustained revenue growth, following a lengthy period of patent expiries. The company is also mired in a serious corruption scandal in China, where it has been accused of paying bribes to doctors to use its medicines. Sales in China were down by a quarter compared to the same period a year ago. Witty told reporters he remained "very concerned" about the allegations in China, which have damaged its business in a fast-growing emerging market, but declined to comment any further.